Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | INCB099280 |
| Trade Name | |
| Synonyms | INCB 099280|INCB-099280|INCB 99280|INCB-99280|INCB99280 |
| Drug Descriptions |
INCB099280 is a small molecule inhibitor of CD274 (PD-L1) that prevents binding to PDCD1 (PD-1), potentially inducing an anti-tumor immune response (J ImmunoTherapy Cancer 2022;10, NCI Drug Dictionary). |
| DrugClasses | Immune Checkpoint Inhibitor 150 PD-L1 Inhibitor 15 |
| CAS Registry Number | NA |
| NCIT ID | C200856 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Adagrasib + INCB099280 | Adagrasib INCB099280 | 0 | 1 |
| Axitinib + INCB099280 | Axitinib INCB099280 | 0 | 1 |
| INCB099280 | INCB099280 | 0 | 4 |
| INCB099280 + Ipilimumab | INCB099280 Ipilimumab | 0 | 1 |